Vmn2r113 Inhibitors
Vmn2r113 inhibitors pertain to a specialized class of chemical compounds that interact with a specific type of receptor within the chemosensory system, the Vmn2r113 receptor. These receptors are encoded by a cluster of genes known as the Vomeronasal Type-2 Receptor 113 (Vmn2r113) genes and are part of the vomeronasal system, which is implicated in the detection of pheromones and other chemical signals that influence social and reproductive behaviors in some mammals. The Vmn2r113 inhibitors are characterized by their ability to bind to these receptors, effectively blocking the receptor's normal function of binding to its natural ligands. This interaction is highly selective, meaning that these inhibitors are typically designed or discovered based on their high affinity and specificity for the Vmn2r113 receptor, with minimal effects on other types of receptors within the vomeronasal system or other chemosensory systems.
The design and study of Vmn2r113 inhibitors involve a deep understanding of molecular biology, chemistry, and the structure-activity relationship (SAR) that governs receptor-ligand interactions. Scientists utilize various methods such as in silico modeling, high-throughput screening, and medicinal chemistry to identify and optimize these inhibitors. The molecular architecture of Vmn2r113 inhibitors can vary widely, encompassing a range of small molecules, peptides, or other synthetic compounds. These molecules often possess specific structural features that are critical for their inhibitory function, such as particular binding domains that interact with corresponding regions on the receptor. The development and examination of these inhibitors contribute significantly to the fundamental knowledge of chemosensory receptor function and the complex mechanisms by which animals perceive their environment at the chemical level. Research in this area sheds light on the intricate network of interactions that underlie the chemical senses and the molecular intricacies of receptor signaling and inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, it can downregulate downstream signaling pathways such as PI3K/AKT and MAPK, which might lead to indirect suppression of Vmn2r113 expression or activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can lead to the inhibition of the PI3K/AKT/mTOR pathway, a crucial signaling route for cell growth and proliferation. This could indirectly decrease the expression levels of Vmn2r113 in cells. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor that can attenuate the PI3K/AKT signaling pathway, potentially reducing the stability or expression of Vmn2r113 as a downstream effect. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that interrupts the MAPK/ERK pathway. By blocking this pathway, it could lead to a reduction in the expression or activity of Vmn2r113 due to the pathway's role in gene expression regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that may disrupt inflammatory signaling pathways. Since Vmn2r113 could be regulated by inflammatory signals, inhibition of p38 MAPK may lead to reduced expression or function of Vmn2r113. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor similar to PD98059, but potentially more potent and selective. It could lead to decreased Vmn2r113 activity by inhibiting the MAPK/ERK pathway, which might be involved in the regulation of Vmn2r113. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible PI3K inhibitor. By inhibiting PI3K, it could decrease AKT activation, which may indirectly lower Vmn2r113 expression or disrupt its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can influence cell survival and apoptosis. Inhibition of JNK might indirectly decrease Vmn2r113 activity if Vmn2r113 is involved in JNK-related signaling pathways. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor that prevents AKT phosphorylation and activation. By inhibiting AKT, it could indirectly affect the expression or function of Vmn2r113, assuming Vmn2r113 is downstream of AKT signaling. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin is a flavone that can inhibit protein kinase C (PKC). Since PKC participates in a wide range of cellular signaling pathways, its inhibition could affect pathways that regulate Vmn2r113 activity. | ||||||